Jasper Therapeutics’ (JSPR) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report released on Tuesday morning, Benzinga reports.

Several other equities analysts have also weighed in on JSPR. TD Cowen started coverage on shares of Jasper Therapeutics in a report on Monday, March 18th. They set an outperform rating on the stock. HC Wainwright restated a buy rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Wednesday, May 15th. Oppenheimer restated an outperform rating and issued a $80.00 target price on shares of Jasper Therapeutics in a report on Thursday, March 7th. Royal Bank of Canada started coverage on shares of Jasper Therapeutics in a report on Thursday, March 28th. They issued an outperform rating and a $70.00 target price on the stock. Finally, Evercore ISI started coverage on shares of Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an outperform rating and a $65.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $64.29.

Jasper Therapeutics Trading Down 4.6 %

Shares of NASDAQ JSPR opened at $23.19 on Tuesday. The firm’s 50-day moving average price is $23.67 and its 200-day moving average price is $18.59. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01. The firm has a market capitalization of $349.24 million, a P/E ratio of -4.12 and a beta of 2.24.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.23. Equities research analysts forecast that Jasper Therapeutics will post -4.36 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors have recently added to or reduced their stakes in JSPR. Opaleye Management Inc. bought a new stake in Jasper Therapeutics in the 4th quarter worth about $3,144,000. Kingdon Capital Management L.L.C. grew its position in shares of Jasper Therapeutics by 16.4% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after acquiring an additional 500,000 shares during the period. Monaco Asset Management SAM bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at approximately $197,000. StemPoint Capital LP bought a new position in shares of Jasper Therapeutics during the 1st quarter valued at approximately $3,794,000. Finally, Ikarian Capital LLC bought a new position in shares of Jasper Therapeutics during the 1st quarter valued at approximately $3,088,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.